"Designing Growth Strategies is in our DNA"
Neurological disease continues to remain a global burden owing to the lack of proper treatment. Progressive Multifocal Leukoencephalopathy, is one such rare neurological disorder in which the cells responsible for the production of myelin are destroyed. Myelin is essential for the central nervous system as it protects the nerve cells in the brain and spinal cord. It is caused by John Cunningham Virus (JCV), named after the patient in whom it was discovered. Symptoms of progressive multifocal leukoencephalopathy include lesions, loss of coordination, facial drooping, weakness, and others.
John Cunningham Virus (JCV) is found in up to 85% of the adult population and causes disease in multiple areas of the brain. According to the National Organization of Rare Disorders, 4,000 people every year develop progressive multifocal leukoencephalopathy in the U.S, and Europe combined. Current treatment for progressive multifocal leukoencephalopathy is the reversal or removal of source causing immunosuppression. This can be done through plasma exchange which enable the removal of agents that puts the patients at risk of developing progressive multifocal leukoencephalopathy.
Lack of effective therapy to block JCV without toxicity have encouraged many pharmaceutical and research institutes for conducting clinical study on progressive multifocal leukoencephalopathy. For instance; PyVST is a polyomavirus-specific T-Cells, which is being studied by the National Institute of Neurological Disorders and Stroke (NINDS) and is currently in phase 1 clinical trials for the treatment of progressive multifocal leukoencephalopathy.
At present around 43% of the pipeline candidates for Progressive Multifocal Leukoencephalopathy are in the phase 2 stage. More than half of the studies are sponsored by government research institutes.
To know how our report can help streamline your business, Speak to Analyst
The report on ‘Progressive Multifocal Leukoencephalopathy – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Progressive Multifocal Leukoencephalopathy. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Progressive Multifocal Leukoencephalopathy.
The report on ‘Progressive Multifocal Leukoencephalopathy – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.